Agranulocytosis due to secondary exposure to antithyroid drugs in a relapsed Graves' disease patient.
- Author:
Gwi Hong JEONG
1
;
Seong Kyun KIM
;
Dae Seong MYUNG
;
Jin Ook CHUNG
;
Dong Hyeok CHO
;
Dong Jin CHUNG
;
Min Young CHUNG
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. mychung@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Graves' Disease;
Recurrence;
Antithyroid agents;
Agranulocytosis
- MeSH:
Agranulocytosis;
Antithyroid Agents;
Graves Disease;
Humans;
Korea;
Recurrence
- From:Korean Journal of Medicine
2008;75(3):362-366
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Antithyroid drugs are the most common treatment modality for Graves' disease and are used for the treatment of relapsed Graves' disease in Korea. Agranulocytosis is a rare and severe complication of antithyroid drug therapy, and most cases occur within 3 month after drug treatment. Agranulocytosis can develop in patients who have relapsed Graves' disease and undergo a second course of antithyroid drugs with a prior uneventful course of drug therapy. We report a case of antithyroid drug-induced agranulocytosis in a relapsed Graves' disease patient who had undergone prior uneventful antithyroid drug therapy. We also present a review of the relevant literature.
